Second, wild-type p53 promotes the tumor upregulation of natural killer (NK) cell-activating NKG2D ligands ULBP1 and ULBP2 [170], and induces miR-34a, which represses tumor expression of the T-cell inhibitory molecule PD-L1 [171]. Here, ULBP2 is linked to neoplasm.